Mycobacterium haemophilum: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 45: Line 45:
==Treatment==
==Treatment==
===Antimicrobial regimen===
===Antimicrobial regimen===
* Agents active in vitro
:* Preferred regimen: [[Amikacin]], [[Clarithromycin]], [[Ciprofloxacin]], [[Rifampin]], and [[Rifabutin]]
:* Alternative regimen: [[Doxycycline]] and [[Sulfonamides]]
* Disseminated disease
:* Preferred regimen: [[Clarithromycin]] {{and}} [[Rifampin]] {{and}} [[Rifabutin]] {{and}} [[Ciprofloxacin]]


==References==
==References==

Revision as of 18:19, 6 July 2015

Mycobacterium haemophilum
Scientific classification
Kingdom: Bacteria
Phylum: Actinobacteria
Order: Actinomycetales
Suborder: Corynebacterineae
Family: Mycobacteriaceae
Genus: Mycobacterium
Species: M. haemophilum
Binomial name
Mycobacterium haemophilum
Sompolinsky et al. 1978, ATCC 29548

WikiDoc Resources for Mycobacterium haemophilum

Articles

Most recent articles on Mycobacterium haemophilum

Most cited articles on Mycobacterium haemophilum

Review articles on Mycobacterium haemophilum

Articles on Mycobacterium haemophilum in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mycobacterium haemophilum

Images of Mycobacterium haemophilum

Photos of Mycobacterium haemophilum

Podcasts & MP3s on Mycobacterium haemophilum

Videos on Mycobacterium haemophilum

Evidence Based Medicine

Cochrane Collaboration on Mycobacterium haemophilum

Bandolier on Mycobacterium haemophilum

TRIP on Mycobacterium haemophilum

Clinical Trials

Ongoing Trials on Mycobacterium haemophilum at Clinical Trials.gov

Trial results on Mycobacterium haemophilum

Clinical Trials on Mycobacterium haemophilum at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mycobacterium haemophilum

NICE Guidance on Mycobacterium haemophilum

NHS PRODIGY Guidance

FDA on Mycobacterium haemophilum

CDC on Mycobacterium haemophilum

Books

Books on Mycobacterium haemophilum

News

Mycobacterium haemophilum in the news

Be alerted to news on Mycobacterium haemophilum

News trends on Mycobacterium haemophilum

Commentary

Blogs on Mycobacterium haemophilum

Definitions

Definitions of Mycobacterium haemophilum

Patient Resources / Community

Patient resources on Mycobacterium haemophilum

Discussion groups on Mycobacterium haemophilum

Patient Handouts on Mycobacterium haemophilum

Directions to Hospitals Treating Mycobacterium haemophilum

Risk calculators and risk factors for Mycobacterium haemophilum

Healthcare Provider Resources

Symptoms of Mycobacterium haemophilum

Causes & Risk Factors for Mycobacterium haemophilum

Diagnostic studies for Mycobacterium haemophilum

Treatment of Mycobacterium haemophilum

Continuing Medical Education (CME)

CME Programs on Mycobacterium haemophilum

International

Mycobacterium haemophilum en Espanol

Mycobacterium haemophilum en Francais

Business

Mycobacterium haemophilum in the Marketplace

Patents on Mycobacterium haemophilum

Experimental / Informatics

List of terms related to Mycobacterium haemophilum

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Mycobacterium haemophilum

Description

Short, occasionally curved, gram-positive, nonmotile and strongly acid-fast rods.

Colony characteristics

  • Nonpigmented and rough to smooth colonies.

Physiology

  • Media have to be supplemented with 0.4% haemoglobin or 60µM hemin (factor X) or 15mg/ml ferric ammonium citrate respectively, but not with FeCl3 or catalase.
  • Slow growth on Löwenstein-Jensen media or Middlebrook 7H10 agar at 32°C within 2-4 weeks.
  • Growth slower at 25°C and 35°C and absent at 37°C.
  • Strictly intracellular growth in tissue cultures of fibroblasts.

Differential characteristics

  • Unique among mycobacteria in its requirement for hemin or ferric ammonium citrate for growth.

Distribution.

Pathogenesis

Type Strain

First isolated in Israel from a subcutaneous granuloma from a patient with Hodgkin's disease. An environmental reservoir is presumed. Strain ATCC 29548 = CCUG 47452 = CIP 105049 = DSM 44634 = NCTC 11185.

Treatment

Antimicrobial regimen

  • Agents active in vitro
  • Disseminated disease

References

  • Sompolinsky et al. 1978. Mycobacterium haemophilum sp. nov., a new pathogen of humans. International Journal of Systematic Bacteriology, 28, 67-75.


de:Mycobacterium haemophilum nl:Mycobacterium haemophilum

Template:SIB

Template:WikiDoc Sources